ENGN · enGene Therapeutics Inc.
$1.87
-0.07 (-3.61%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Jun 15, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
Market Cap
$125.32M
Shares
67.02M
Volume · Oct 5
952.87K
Avg daily vol (3M)
808.13K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.87
Open$1.94
Day$1.79–1.94
52W close$1.44–12.17
Avg vol 30d755K
Short int1.2M · 1.8% float · 1.7d
Short vol62%
DataFeb 2022–Oct 2026
Filing10-Q · Sep 8
Up next
filed Sep 8, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$130.36M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.8
Trailing earnings · reciprocal yield 125.3%
FCF yield
-79.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$266.32M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.5%
Year over year · more shares
Price change (1Y)
-76.2%
Trailing year
Short interest
1.8%
Latest settlement · 1.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Very Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−63%
below
Price vs 50-day avg
+1%
above
RSI (14)
46
neutral
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
−75%
trailing
YTD return
−79%
this year
Relative strength
−87%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$10.1K over 90 days · 0% sells
Short interest
Falling
1.79% of float · ▼ -2.1% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
70 holders — near 2-yr high, broad support
Squeeze score
47
elevated · 0–100
Fundamentals
EPS growth
+57%
Y/Y
Free cash flow
$-100.7M
Quant / Vol
risk profile
Volatility
120%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jun 15, 2026
Restructuring costs
· second half of 2026
Initiated
$5.7M – $6.4M
Non-cash stock-based compensation expense
· second half of 2026
Initiated
$4.7M – $5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−63%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+13% holders QoQ · +30 funds added
Insider flow
Accumulating
Net +$10.1K over 90 days · 0% sells
Short interest
Falling
1.79% of float · ▼ -2.1% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
70 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 4%
Range high $12
vs 200-day avg -63%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $266.3M | As of July 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENGN
this stock
enGene Therapeutics Inc.
|
$125.32M | -79.3% | — | — | 1.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENGN | -5.1% | +2.8% | -75.4% | -6.5% | -79.3% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -6.3% | +2.2% | -87.0% | -8.1% | -92.9% |